PET imaging of mitochondrial function in acute doxorubicin-induced cardiotoxicity: a proof-of-principle study

[1]  R. Barsotti,et al.  Mitochondrial targeted antioxidants, mitoquinone and SKQ1, not vitamin C, mitigate doxorubicin-induced damage in H9c2 myoblast: pretreatment vs. co-treatment , 2021, BMC Pharmacology and Toxicology.

[2]  N. Alpert,et al.  Quantification of Myocardial Mitochondrial Membrane Potential Using PET , 2021, Current Cardiology Reports.

[3]  T. Marwick,et al.  Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. , 2020, Journal of the American College of Cardiology.

[4]  N. Alpert,et al.  In vivo quantitative mapping of human mitochondrial cardiac membrane potential: a feasibility study , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Monica Sharma,et al.  PET Radiopharmaceuticals for Imaging Chemotherapy-Induced Cardiotoxicity , 2020, Current Cardiology Reports.

[6]  N. Alpert,et al.  In-vivo Imaging of Mitochondrial Depolarization of Myocardium With Positron Emission Tomography and a Proton Gradient Uncoupler , 2020, Frontiers in Physiology.

[7]  Anita Saraf,et al.  Mitochondrial dysfunction and oxidative stress in heart disease , 2019, Experimental & Molecular Medicine.

[8]  Monya Baker,et al.  Reporting animal research: Explanation and Elaboration for the ARRIVE guidelines 2019 , 2019, bioRxiv.

[9]  S. Ait-Oudhia,et al.  Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring , 2019, Molecular Pharmacology.

[10]  R. Gunn,et al.  Imaging of Chemotherapy-Induced Acute Cardiotoxicity with 18F-Labeled Lipophilic Cations , 2019, The Journal of Nuclear Medicine.

[11]  R. Laforest,et al.  68Ga-Galmydar: A PET imaging tracer for noninvasive detection of Doxorubicin-induced cardiotoxicity , 2019, PloS one.

[12]  Manuel Lobo,et al.  Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity. , 2019, Journal of the American College of Cardiology.

[13]  M. Veronese,et al.  Detection of anthracycline-induced cardiotoxicity using perfusion-corrected 99mTc sestamibi SPECT , 2019, Scientific Reports.

[14]  J. Zamorano,et al.  Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology , 2018, European journal of heart failure.

[15]  N. Alpert,et al.  Quantitative in vivo mapping of myocardial mitochondrial membrane potential , 2018, PloS one.

[16]  Tai Kyung Kim,et al.  Early Detection and Serial Monitoring of Anthracycline-Induced Cardiotoxicity Using T1-mapping Cardiac Magnetic Resonance Imaging: An Animal Study , 2017, Scientific Reports.

[17]  P. Menna,et al.  Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview , 2017, Chemotherapy.

[18]  C. Cipolla,et al.  Chemotherapy-induced cardiotoxicity: importance of early detection , 2016, Expert review of cardiovascular therapy.

[19]  Hong Zhu,et al.  Doxorubicin Redox Biology: Redox Cycling, Topoisomerase Inhibition, and Oxidative Stress. , 2016, Reactive oxygen species.

[20]  S. Punwani,et al.  Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis , 2015, Journal of cardiovascular computed tomography.

[21]  G. Dorn,et al.  Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling , 2014, Proceedings of the National Academy of Sciences.

[22]  Paaladinesh Thavendiranathan,et al.  Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. , 2014, Journal of the American College of Cardiology.

[23]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[24]  Eric E Schadt,et al.  The role of macromolecular damage in aging and age-related disease. , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.

[25]  E. Yeh,et al.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity , 2012, Nature Medicine.

[26]  Z. Bosnjak,et al.  Enhanced charge-independent mitochondrial free Ca(2+) and attenuated ADP-induced NADH oxidation by isoflurane: Implications for cardioprotection. , 2012, Biochimica et biophysica acta.

[27]  R. Margreiter,et al.  Changes in mitochondrial redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubicin-induced cell death. , 2011, Biochimica et biophysica acta.

[28]  Randolph P. Martin,et al.  Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. , 2011, The American journal of cardiology.

[29]  A. Fischman,et al.  Evaluation of (4-[18F]Fluorophenyl)triphenylphosphonium Ion. A Potential Myocardial Blood Flow Agent for PET , 2011, Molecular Imaging and Biology.

[30]  T. Gant,et al.  Doxorubicin In Vivo Rapidly Alters Expression and Translation of Myocardial Electron Transport Chain Genes, Leads to ATP Loss and Caspase 3 Activation , 2010, PloS one.

[31]  J. Y. Lee,et al.  Comparison of anaesthetic and cardiorespiratory effects of xylazine or medetomidine in combination with tiletamine/zolazepam in pigs , 2010, Veterinary Record.

[32]  S. Lancel,et al.  Stabilization of mitochondrial membrane potential prevents doxorubicin-induced cardiotoxicity in isolated rat heart. , 2010, Toxicology and applied pharmacology.

[33]  M. Pomper,et al.  Characterization of membrane potential-dependent uptake of the novel PET tracer 18F-fluorobenzyl triphenylphosphonium cation , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  D. Richel,et al.  Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients , 2007, Clinical pharmacokinetics.

[35]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Circulation.

[36]  Peter Herscovitch,et al.  Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission Tomography , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[37]  B. de Kruijff,et al.  Effects of adriamycin on respiratory chain activities in mitochondria from rat liver, rat heart and bovine heart. Evidence for a preferential inhibition of complex III and IV. , 1987, Biochimica et biophysica acta.